Search - tctmd.com

Displaying 61 - 80 of 468

Sort: Relevancy | Date

Presentation TCT 2023

TCT 497: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 4 Clinical Year Outcomes

Presenter: Matthias Lutz

October 25, 2023

Presentation TCT 2023

TCT 591: Preclinical Evaluation of a Novel Bioresorbable Sirolimus Eluting Magnesium-Alloy Scaffold in a Healthy Swine Coronary Arteries up to 540 Days

Presenter: Sho Torii

October 25, 2023

Presentation TCT 2023

TCT 576: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

October 25, 2023

TCT 669: Impact of ACS on Long-Term Clinical Outcomes After PCI With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presentation TCT 2023

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

Presenter: Manijeh Noori

October 24, 2023

News Conference News ESC 2023

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Michael O'Riordan

August 26, 2023

News Conference News EAS 2023

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

Michael O'Riordan

May 25, 2023

Presentation EuroPCR 2023

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

Presenter: Shigeru Saito

May 18, 2023

News Conference News EuroPCR 2023

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Michael O'Riordan

May 18, 2023

Presentation TCT 2022

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

Presenter: Michael Haude

September 19, 2022

Presentation TCT 2022

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

Presenter: Holger Nef

September 19, 2022

Presentation TCT 2022

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

Presenter: Matthias Lutz

September 17, 2022

Presentation TCT 2022

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

Presenter: Matthias Lutz

September 17, 2022

News Industry News

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

September 13, 2022

JSousa1.cropped (002) in memoriam_header

News Daily News

Stent Pioneer José Eduardo Sousa Dies, Age 88

Shelley Wood

March 14, 2022

News Conference News

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Caitlin E. Cox

March 02, 2022

Presentation TCT 2021

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Presenter: Runlin Gao

November 05, 2021

Presentation TCT 2021

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

Presenter: Matthias Lutz

November 04, 2021

News Conference News TCT 2021

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

L.A. McKeown

October 25, 2021

News Conference News TCT 2021

Good Long-term Results With FANTOM BVS, but More Data Needed

Michael O'Riordan

October 21, 2021

News Daily News

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

L.A. McKeown

October 05, 2021

Advertisement

TCT 497: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 4 Clinical Year Outcomes

TCT 591: Preclinical Evaluation of a Novel Bioresorbable Sirolimus Eluting Magnesium-Alloy Scaffold in a Healthy Swine Coronary Arteries up to 540 Days

TCT 576: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final 5 Year Clinical Outcomes

TCT 669: Impact of Acute Coronary Syndromes on Long-Term Clinical Outcomes After Percutaneous Coronary Intervention With the Biolimus-Coated BioFreedom Stent or Biodegradable Polymer Sirolimus-Eluting Orsiro Stent: From the SORT OUT IX Trial

FIRE: Complete Revascularization Best Even for Elderly Patients With MI

Newest Resorbable Magnesium Scaffold Shows Promise in BIOMAG-1

BIOADAPTOR RCT: Randomized Controlled Trial of Sirolimus-Eluting Bioadaptor Scaffold Versus Zotarolimus-Eluting Drug-Eluting Stent

‘Fascinating’ Unlocking Coronary Stent Prompts Cautious Praise

Safety and Performance of a Sirolimus Eluting Resorbable Coronary Magnesium Scaffold (DREAMS 3G): The BIOMAG-1 FIH Trial

TCT 155: The Bioadaptor RCT Study: Comparison of a Novel Sirolimus-Eluting Bioadaptor with Zotarolimus-Eluting Stent in de novo Coronary Arteries

TCT 64: FANTOM II Long Lesion Study: Initial Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold in Long Lesions – 3 Clinical Year Outcomes

TCT 58: FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – Final: 5 Year Clinical Outcomes

TRANSFORM 1 Enrollment Completed: A Crucial RCT ready to redefine the DCB Angioplasty Mechanism

Stent Pioneer José Eduardo Sousa Dies, Age 88

BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

FANTOM II Trial: Safety & Performance Study of the Fantom Sirolimus-Eluting Bioresorbable Coronary Scaffold – First Report: Final 5 Year Clinical Outcomes

OPTIMIZE: 2-Year DES Data Affirm Need for Meaningful MI Definitions

Good Long-term Results With FANTOM BVS, but More Data Needed

Cardiac Deaths and Adverse Events After PCI Have Declined With Time

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content